MacroGenics’ updated presentation reports MGC026 best overall response rate of 27% in late-line SCCHN, with 64% disease control rate, and $288M in cash and marketable securities supporting cash runway guidance through 2028.
MGNX · Macrogenics Inc · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
MacroGenics held $287.7 million in cash, cash equivalents and marketable securities, with cash runway guidance through 2028. It reported a third-quarter net loss of $20.1 million, completed MGC028 dose escalation and dosed the first patient in MGC030’s Phase 1 study.
Macrogenics sold its CDMO Operations to Bora for a $122.5 million purchase price and received $119.6 million after adjustments, recognizing an $87.5 million pretax gain. Cash runway is expected through 2028, dependent on future partner payments and cost savings.
MacroGenics appointed Emil Kuriakose, M.D. and Michael Vasconcelles, M.D. as independent directors effective October 30, 2026, expanding its board from ten to eleven members.
MacroGenics reported interim Phase 1 MGC026 data showing a 27% best overall response rate in heavily pretreated SCCHN patients, with no treatment-related discontinuations, and plans an early 2027 front-line pembrolizumab combination cohort.